Table 4.
Clinical trials of NK cells for cancer immunotherapy listed on https://www.clinicaltrials.gov/ (1 November 2019–1 November 2022, accessed on 11 November 2022).
| NCT Number | Infused Cells | Diseases | Phases | Enrollment | Status |
|---|---|---|---|---|---|
| NCT03937895 | Allogeneic NK Cells | Biliary Tract Cancer | I/II | 40 | Completed |
| NCT04616209 | Allogeneic NK Cells | Non-small Cell Lung Cancer | I/II | 24 | Recruiting |
| NCT04847466 | Irradiated PD-L1 CAR-NK Cells | Recurrent/Metastatic Gastric or Head and Neck Cancer | II | 55 | Recruiting |
| NCT05213195 | NKG2D CAR-NK Cells | Refractory Metastatic Colorectal Cancer | I | 38 | Recruiting |
| NCT03329664 | Cytokine-induced Killer (CIK) Cells | Colon Cancer Stage IV | I/II | 20 | Recruiting |
| NCT04872634 | NK01 (Super Natural Killer Cells 01) | Non-small Cell Lung Cancer | I/II | 24 | Recruiting |
| NCT05194709 | Anti-5T4 CAR-NK Cells | Advanced Solid Tumors | I (early) | 40 | Recruiting |
| NCT04290546 | cytokine-induced memory-like NK (CIML-NK) cells | Squamous Cell Carcinoma of the Head and Neck | I | 12 | Recruiting |
| NCT05020678 | NKX019 | B-cell Malignancies | I | 60 | Recruiting |
| NCT04796675 | Anti-CD19 CAR-NK Cells | B Lymphoid Malignancies | I | 27 | Recruiting |
| NCT05099549 | SNK01 | Advanced/Metastatic EGFR-Expressing Cancers | I/II | 121 | Recruiting |
| NCT04143711 | DF1001 | Solid Tumor, Adult | I/II | 220 | Recruiting |
| NCT04319757 | ACE1702 | HER2-expressing Solid Tumors | I | 36 | Recruiting |
| NCT04310592 | CYNK-001 | Acute Myeloid Leukemia, Adult | I | 94 | Recruiting |
| NCT05069935 | FT538 | Solid Tumor, Adult | I | 189 | Recruiting |
| NCT04634435 | CIML NK Cells | Multiple Myeloma | I/II | 25 | Recruiting |
| NCT05304754 | Alloreactive NK cells | High-risk Leukemias | I/II | 18 | Recruiting |
| NCT05008536 | Anti-BCMA CAR-NK Cells | Multiple Myeloma, Refractory | I (early) | 27 | Recruiting |
| NCT04623944 | NKX101-CAR NK Cells | Acute Myeloid Leukemia, Adult | I | 90 | Recruiting |
| NCT04558931 | Autologous NK Cells | Multiple Myeloma | II | 60 | Recruiting |
| NCT04901416 | Allogeneic NK Cells | Acute Myeloid Leukemia, Adult | I | 18 | Recruiting |
| NCT04309084 | CYNK-001 | Multiple Myeloma | I | 29 | Active, not recruiting |
| NCT04630769 | FT516 | Ovarian Cancer | I | 3 | Completed |
| NCT05379647 | NK Cells | B-Cell Malignancies | I | 24 | Recruiting |
| NCT04259450 | AFM24 | Advanced Solid Tumor | I/II | 155 | Recruiting |
| NCT03821519 | Cytokine-induced Killer (CIK) Cells | Relapsed Hematologic Malignancy | I/II | 20 | Recruiting |
| NCT04347616 | UCB-NK Cells | Acute Myeloid Leukemia, Adult | I/II | 23 | Recruiting |
| NCT05247957 | NKG2D CAR-NK Cells | Safety and Efficacy | I | 9 | Recruiting |
| NCT05008575 | Anti-CD33 CAR-NK Cells | Acute Myeloid Leukemia | I | 27 | Recruiting |
| NCT05215015 | Anti-CD33/CLL1 CAR-NK Cells | Acute Myeloid Leukemia | I (early) | 18 | Recruiting |
| NCT04220684 | Haploidentical NK Cells | Acute Myeloid Leukemia | I | 30 | Recruiting |
| NCT03539406 | UCB-NK Cells | Recurrent Ovarian Carcinoma | I | 12 | Recruiting |
| NCT05333705 | Allogeneic NK Cells | Acute Myeloid Leukemia | I | 15 | Recruiting |
| NCT04836390 | Haploidentical NK Cells | Acute Myeloid Leukemia | II | 30 | Enrolling by invitation |
| NCT04898543 | M-CENK | Metastatic Solid Tumor | I | 30 | Recruiting |
| NCT04551885 | FT516 | Solid Tumor, Adult | I | 12 | Active, not recruiting |
| NCT05182073 | FT576 | Multiple Myeloma | I | 168 | Recruiting |
| NCT03348033 | Autologous NK Cells | Chronic Myeloid Leukemia | I/II | 5 | Enrolling by invitation |
| NCT04614636 | FT538 | Advanced Hematologic Malignancies | I | 105 | Recruiting |
| NCT04162158 | Allogeneic NK Cells | Hepatocellular Carcinoma | I/II | 200 | Recruiting |
| NCT05108012 | NK Cells | Glioblastoma Multiform | I | 5 | Recruiting |
| NCT02573896 | NK Cells | Neuroblastoma | I | 13 | Active, not recruiting |
| NCT04802070 | Autologous CIK Cells | Sarcoma | I | 36 | Recruiting |
| NCT04887012 | Anti-CD19 CAR-NK Cells | B-cell Non-Hodgkin Lymphoma | I | 25 | Recruiting |
| NCT04489420 | CYNK-001 | Glioblastoma | I | 3 | Terminated |
| NCT04074746 | AFM13-NK | Recurrent/Refractory CD30 Positive Lymphomas | I/II | 30 | Recruiting |
| NCT05137275 | Anti-5T4 CAR-raNK Cells | Locally Advanced or Metastatic Solid Tumors | I (early) | 56 | Recruiting |